The client, with an established national field sales footprint, looked to partner to improve the stagnant sales trajectory for their I/O delivery device.
A field team of 16 DSAs (diabetes representatives) was overlayed to existing team to support high and medium-value targets to improve impact and call frequency.
DSAs’ goals also included elevating brand perception not just to the targeted HCPs but through a total account call to maximize pull-through adjacent to clinical selling.
Within the first four months of the added team, high-value DSA targets were averaging 3.5 more Rxs per target compared to the control group.
Average DSA had 21% more call activity (and 12% more sampling) than incumbent team.
Call activity (reach and frequency) was improved while contributing to a significant improvement in the cost per call (82% savings) for DSA targets.
Qualitative (market effectiveness surveys) feedback also showed improved brand and message recall and DSA satisfaction.
Wave 1:
93% of respondents state that they are ‘very satisfied’ with their DSA.**
**7% state that they are ‘satisfied’.
Jump to a slide with the slide dots.
Explore how continuous optimization, AI-powered insights, and agile commercial models help pharmaceutical companies drive growth beyond launch.
Read more
Discover how Inizio Engage helped a rare disease biotech reduce commercial launch risk through HCP mapping, referral pathway analysis and...
Read more
Discover how AI, customer experience, and intelligent field teams are reshaping HCP engagement strategies across the pharmaceutical product lifecycle.
Read more
Discover how learning systems, AI, and continuous optimisation are transforming pharmaceutical commercial strategy and HCP engagement.
Read more